PureTech Health (LON:PRTC) Stock Price Up 14.2% - Still a Buy?

Key Points

• PureTech Health's shares surged by 14.2% during mid-day trading, reaching prices as high as GBX 123.80 ($1.67) before closing at GBX 121.50 ($1.64).
• The company has a market capitalization of £293.65 million and a price-to-earnings ratio of 714.71, indicating high valuation volatility.
• Insider Bharatt Chowrira purchased 167,739 shares at £1 per share, reflecting confidence in the company's long-term prospects.

PureTech Health plc (LON:PRTC - Get Free Report) was up 14.2% during mid-day trading on Saturday . The stock traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares traded hands during trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.44).

PureTech Health Price Performance

The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The stock has a market cap of £303.07 million, a price-to-earnings ratio of 737.65 and a beta of 1.02. The business's 50-day simple moving average is GBX 129.31 and its two-hundred day simple moving average is GBX 129.65.

Insiders Place Their Bets

In related news, insider Bharatt Chowrira bought 167,739 shares of the business's stock in a transaction on Thursday, July 3rd. The shares were purchased at an average price of GBX 1 per share, for a total transaction of £1,677.39. 13.13% of the stock is owned by corporate insiders.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.